Efinaconazole 10% solution: A new topical antifungal therapy for onychomycosis

Expert Review of Dermatology

Volumn 8, Issue 4, 2013, Pages 347-356

  Elewski, Boni E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

efficacy; efinaconazole; nonclinical; onychomycosis; safety; topical triazole antifungal

Indexed keywords

EID: 84883128435     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.2013.814872     Document Type: Review

References (60)

1. Scher RK, Coppa LM. Advances in the diagnosis and treatment of onychomycosis. Hosp. Med. 34, 11-20 (1998
2. Crissey JT. Common dermatophyte infections. A simple diagnostic test and current management. Postgrad. Med. 103(2), 191-1, 197-200, 205 (1998
3. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: A multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. 43, 244-248 (2000
4. Roberts DT. Onychomycosis: Current treatment and future challenges. Br. J. Dermatol. 141(Suppl. 56), 1-4 (1999
5. Finch JJ, Warshaw EM. Toenail onychomycosis: Current and future treatment options. Dermatol. Ther. 20, 31-46 (2007
6. Kumar S, Kimball AB. New antifungal therapies for the treatment of onychomycosis. Expert Opin. Investig. Drugs 18, 727-734 (2009
7. Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J. Am. Acad. Dermatol. 43(4), 641-648 (2000
8. Elewski BE. Onychomycosis: Pathogenesis, diagnosis, and management. Clin. Microbiol. Rev. 11, 415-429 (1998
9. Heikkla H, Stubb S. The prevalence of onychomycosis in Finland. Br. J. Dermatol. 133, 699-703 (1995
10. Scher RK. Onychomycosis: Therapeutic update. J. Am. Acad. Dermatol. 40, S21-S26 (1999
11. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch. Dermatol. 133, 1172-1173 (1997
12. Seebacher C, Brasch J, Abeck D et al. Onychomycosis. Mycoses 50, 321-327 (2007
13. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandell, Douglas, and Bennett's Principles And Practice Of Infectious Diseases (6th Edition). Mandell GL, Bennett JE, Dolin R (Eds). Elsevier Churchill Livingstone, PA, USA, 3051-3062 (2005
14. Nelson MM, Martin AG, Heffernan MP. Superficial fungal infections: Dermatophytosis, onychomycosis, tineanigra, piedra. In: Fitzpatrick's Dermatology in General Medicine (6th Edition). Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds). McGraw-Hill, NY, USA, 1989-2005 (2003
15. Kaur R, Kashyap B, Bhalla P. Onychomycosis -epidemiology, diagnosis and management. Indian J. Med. Microbiol. 26, 108-116 (2008
16. Daniel CR III, Norton LA, Scher RK. The spectrum of nail disease in patients with human immunodeficiency virus infection. J. Am. Acad. Dermatol. 27, 93-97 (1992
17. Baran G, Hay RJ, Tosti A et al. A new classification of onychomycosis. Br. J. Dermatol. 139, 567-571 (1992
18. Drake LA, Scher RK, Smith EB et al. Effect of onychomycosis on quality of life. J. Am. Acad. Dermatol. 38, 702-704 (1998
19. Assaf RR, Elewski BE. Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study. J. Am. Acad. Dermatol. 35(2 Pt 1), 216-219 (1996
20. Jones ED. Onychomycosis: Current treatment options. J. Am. Acad. Nurse Practictioners 15(4), 165-169 (2003
21. Scher RK. Onychomycosis, a significant medical disorder. J. Am. Acad. Dermatol. 35(3 Pt 2), S2-5 (1996
22. Drake LA, Patrick DL, Fleckman P et al. The impact of onychomycosis on quality of life: Development of an international onychomycosis questionnaire to measure patient quality of life. J. Am. Acad. Dermatol. 41, 189-196 (1999
23. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with onychomycosis. Qual. Life Res. 2, 341-348 (1993
24. Schein JR, Gause D, Stier DM et al. Onychomycosis: Baseline results of an observational study. J. Am. Pod. Med. Ass. 87(11), 512-519 (1997
25. Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin. Exp. Dermatol. 22, 87-89 (1997
26. Baran R, Sigurgeirsson B, de Berker D, Kaufman R et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br. J. Dermatol. 157, 149-157 (2007
27. Prescrire R. Fungal nail infections: Diagnosis and management. Prescrire. Int. 18, 26-30 (2009
28. Sporanox (itraconazole) [prescribing information]. Janssen, Titusville, NJ, USA (2012
29. Lamisil (terbinafine HCl) [prescribing information]. Novartis, NJ, USA (2012
30. deBerker D. Fungal nail disease. N. Engl. J. Med. 360, 2108 -2116 (2009
31. No authors listed. Ciclopirox (Penlac) nail lacquer for onychomycosis. Med. Lett. Drugs Ther. 42(1080), 51-52 (2000
32. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J. Am. Podiatr. Med. Assoc. 90, 495-501 (2000
33. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy. J. Eur. Acad. Dermatol. Venereol. 19(1), 21-29 (2005
34. Lecha M, Effendy I, Feuilhade de Chauvin M et al. Treatment options -development of consensus guidelines. J. Eur. Acad. Dermatol. Venereol. 19(Suppl. 1), 25-33 (2005
35. Murdan S. Drug delivery to the nail following topical application. Int. J. Pharm. 236, 1-26 (2002
36. Baker SJ, Hui X, Maibach HI. Progress on new therapeutics for fungal nail infections. Ann. Rep. Med. Chem. 40, 323-334 (2005
37. Mertin D, Lippold BC. In vitro permeability of the human nail and of a keratin membrane from bovine hooves: Influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maxium flux. J. Pharm. Pharmacol. 35, 28-33 (1983
38. Kobayashu Y, Komatsu T, Sumi M et al. In vitro permeation of several drugs through the human plate: Relationship between physicochemical properties and nail permeability of drugs. Eur. J. Pharm. Sci. 21, 471-477 (2004
39. Tatsumi Y, Yokoo M, Senda H et al. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob. Agents Chemother. 46, 3797-3801 (2002
40. Baran R, Tosti A, Hartmane I et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J. Eur. Acad. Dermatol. Venereol. 23(7), 773-781 (2009
41. Bhatt V, Sarpotdar P, Pillai R et al. Development of an optimal formulation for efinaconazole a novel antifungal agent for the treatment of onychomycosis by topical application. Presented at: 71st Annual Meeting, American Academy of Dermatology. Miami Beach, FL, USA, 1-15 March 2013
42. Sugiura K, Hosaka S, Arakawa Y et al. Unique properties of efinaconazole 10% solution, a new topical treatment for onychomycosis. Presented at: 71st Annual Meeting, American Academy of Dermatology. Miami Beach, FL, USA, 1-15 March 2013
43. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophyte molds: Clinical features and response to treatment in 59 cases. J. Am. Acad. Dermatol. 42, 217-224 (2000
44. Jo Siu WJ, Tatsumi Y, Senda H et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob. Agents Chemother. 57(4), 1610-1616 (2013
45. Tatsumi Y, Jo W, Mutter L et al. In vitro antifungal activity of efinaconazole, a novel triazole antifungal against a variety of pathogenic fungi. Presented at: 71st Annual Meeting, American Academy of Dermatology. Miami Beach, FL, USA, 1-15 March 2013
46. Jo W, Nakamura T, Iwata A et al. Drug susceptibility and resistance of fungal isolates in onychomycosis against efinaconazole. Presented at: 71st Annual Meeting, American Academy of Dermatology. Miami Beach, FL, USA, 1-15 March 2013
47. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12, 40-79 (1999
48. Tatsumi Y, Nagashima M, Shibanushi T et al. Mechanism of antifungal action of efinaconazole, a novel triazole agent. Antimicrob. Agents Chemother. 57(5), 2405-2409 (2013
49. Hashiguchi T, Kodama A, Ryu A et al. Retention capacity of topical imidazole antifungal agents in the skin. Int. J. Pharm. 161(2), 195-204 (1998
50. Murthy NS, Wiskirchen DE, Bowers CP. Iontophoretic drug delivery across human nail. J. Pharm. Sci. 96(2), 305-311 (2007
51. Elewski BE, Ghannoum MA, Mayser P et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: Results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J. Eur. Acad. Dermatol. Venereol. 27, 287-294 (2013
52. Elewski BE, Rich P, Pollak R et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two Phase 3 multicenter, randomized, double-blind studies. J. Am. Acad. Dermatol. 68, 600-608 (2013
53. Vickers AE, Sinclair JR, Zollinger M et al. Multiple cytochrome P-450sb involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab. Dispos. 27, 1029-1038 (1999
54. Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther. Drug Monit. 27, 680-682 (2005
55. Schatz F, Brautigam M, Dobrowolski E et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin. Exp. Dermatol. 20, 377-383 (1995
56. Park YM. Prolonged drug-drug interaction between terbinafine and perphenazine. Psychiatry Investig. 9, 422-424 (2012
57. Crean C, Kang R, Oh A et al. Minimal systemic exposure of a topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment. Presented at: 71st Annual Meeting, American Academy of Dermatology. Miami Beach, FL, USA, 1-15 March 2013
58. Rich P. Topical treatment of onychomycosis with efinaconazole solution 10%. Cutis 91, 305-307 (2013
59. Gupta AK. Topical treatment of onychomycosis: A realistic option to systemic therapy (a case report). J. Am. Podiatr. Med. Assoc. (In press
60. Carney C, Tosti A, Daniel R et al. A new classification system for grading the severity of onychomycosis: Onychomycosis Severity Index. Arch. Dermatol. 147(11), 1277-1282 (2011